Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

The study of immunology has led to breakthroughs in treating non-small cell lung cancer (NSCLC). The recent approval of an anti-PD1 checkpoint drug for NSCLC has generated much interest in novel combination therapies that might provide further benefit for patients. However, a better understanding of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Transl Lung Cancer Res
Egile Nagusiak: Schoenhals, Jonathan E., Seyedin, Steven N., Anderson, Clark, Brooks, Eric D., Li, Yun R., Younes, Ahmed I., Niknam, Sharareh, Li, Ailin, Barsoumian, Hampartsoum B., Cortez, Maria Angelica, Welsh, James W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2017
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5420535/
https://ncbi.nlm.nih.gov/pubmed/28529897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2017.03.06
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak